Thrombophilia in Pregnancy: An India Guide to APS, Clots and LMWH

• Pregnancy naturally makes blood clot more easily; thrombophilia adds to that and is treatable when correctly diagnosed.
• Antiphospholipid syndrome (APS) is the single most important pregnancy thrombophilia because it is treatable, raising APS live-birth rates from roughly 25 to 80 percent with aspirin plus heparin.
• Inherited thrombophilias (like factor V Leiden) are rare in Indian women, so blanket screening has low value; testing should be targeted to specific personal and obstetric histories.
• APS is diagnosed only when both a clinical event AND a positive antibody test (confirmed on a repeat 12 weeks later) are present.
• Low-molecular-weight heparin (LMWH, usually enoxaparin/Clexane) is the anticoagulant of choice in pregnancy; warfarin and the newer oral blood thinners are not safe in pregnancy.
• The first six weeks after delivery carry the highest clot risk of the whole journey, so postpartum prevention and knowing the warning signs are essential.

Your body constantly balances clotting (to stop bleeding) against keeping blood flowing freely. In thrombophilia that balance tips toward clotting, either because of an inherited gene change affecting your clotting proteins or because of an acquired condition such as antiphospholipid syndrome.

Pregnancy itself shifts you toward clotting on purpose. Clotting factors rise, the natural anticoagulant free protein S falls, and the body's clot-dissolving system slows down, all to reduce blood loss at delivery. This is why a clot is roughly four to five times more common during pregnancy than outside it, even in healthy women. A thrombophilia simply adds to this background tendency.

Thrombophilias fall into two groups. Acquired thrombophilia (mainly APS) is the most important in pregnancy because it is both common enough to matter and uniquely treatable. Inherited thrombophilias, such as factor V Leiden, prothrombin G20210A, and deficiencies of antithrombin, protein C or protein S, mostly raise clot risk and have a weaker link to pregnancy loss.

The Indian picture has its own features. Factor V Leiden and the prothrombin gene mutation, the two most common inherited thrombophilias in Europeans (3 to 5 percent and 2 to 3 percent), are uncommon in Indian women (under 1 percent). So an inherited cause is a less likely explanation for pregnancy problems here, and routine screening finds little. APS, on the other hand, affects Indian women at similar rates to the rest of the world and is the priority to identify. Cost also shapes decisions: a full thrombophilia panel runs roughly Rs 5,000 to 15,000 at private labs, and a course of LMWH across a pregnancy can run into lakhs, which is exactly why testing should be targeted rather than blanket. Free comprehensive care is available at government tertiary centres such as AIIMS, PGI Chandigarh and major state medical colleges.

Antiphospholipid syndrome is an autoimmune condition in which the immune system makes antibodies against phospholipids, the building blocks of cell membranes. These antibodies promote clotting in the mother's veins and arteries and in the tiny vessels of the placenta, which is how APS causes pregnancy problems. It is more common in women with autoimmune disease such as lupus (SLE).

APS is worth identifying because treatment works. Pregnancy complications associated with APS include three or more early miscarriages, mid-trimester and late losses, stillbirth, severe early-onset preeclampsia (before 34 weeks), severe growth restriction needing early delivery, and placental abruption. If you have had repeated losses, APS testing is part of a structured recurrent miscarriage workup.

The diagnosis is strict and deliberately so. It requires BOTH a clinical event AND a confirmed laboratory finding:

• Clinical: a blood clot, OR specific pregnancy events (one loss of a normal baby at 10 weeks or later; one birth before 34 weeks for severe preeclampsia or placental failure; or three or more consecutive early miscarriages before 10 weeks).
• Laboratory: a positive lupus anticoagulant, anticardiolipin antibody, or anti-beta-2 glycoprotein I antibody in medium-to-high titre, confirmed on a second test at least 12 weeks later.

Inherited thrombophilias are gene changes passed down in families that tilt the blood toward clotting. They mainly raise the risk of a clot rather than miscarriage, and their relevance in India differs from Western textbooks.

• Factor V Leiden: the commonest inherited thrombophilia in Europeans but rare in Indian women (under 1 percent). One copy raises clot risk modestly; two copies (much rarer) raise it a lot.
• Prothrombin G20210A: also common in Europeans, rare in India. One copy roughly doubles or triples clot risk.
• Antithrombin deficiency: very rare but the highest-risk inherited thrombophilia.
• Protein C and protein S deficiency: rare, moderate risk. Free protein S normally drops by a third to a half in pregnancy, so this test is unreliable during pregnancy and is best checked beforehand or several weeks after delivery.
• MTHFR mutations: commonly added to private-lab panels in India, but current guidelines (ACMG, ACOG) advise against testing for them. They are not a meaningful cause of clots or pregnancy complications, and the only relevant step, folic acid, is already standard in pregnancy.

Testing everyone is not useful; it should follow specific personal or obstetric histories. This keeps cost down and avoids confusing, hard-to-interpret results.

Test based on your history, not as a routine, if you have:

The APS panel is the core of testing because it is the treatable one: lupus anticoagulant, anticardiolipin antibodies (IgG and IgM), and anti-beta-2 glycoprotein I antibodies, repeated after 12 weeks for confirmation. Inherited thrombophilia tests (antithrombin, protein C, free protein S, factor V Leiden and prothrombin gene by PCR) are added only when there is a clear indication.

Timing changes how reliable the results are:

• Ideally test before pregnancy or at least 12 weeks after delivery, when pregnancy's effects on the blood have settled.
• Free protein S falls in pregnancy, so a low result during pregnancy can be misleading.
• Heparin interferes with the lupus anticoagulant test, so it is best checked before starting treatment.
• After an acute clot, levels of antithrombin, protein C and protein S can be temporarily consumed, so testing is delayed until weeks to months later.

Low-molecular-weight heparin (LMWH) is the anticoagulant of choice in pregnancy. The most widely used in India is enoxaparin, sold as Clexane and several generics (Sun, Cipla, Lupin and others), given as a small subcutaneous injection.

Why LMWH rather than tablets:

• It does not cross the placenta, so it does not harm the baby. Warfarin does cross and can cause birth defects in the first trimester, and the newer direct oral anticoagulants (rivaroxaban, apixaban, dabigatran) are not safe in pregnancy or breastfeeding.
• It is a once- or twice-daily injection rather than a hospital drip.
• It carries a lower risk of heparin-induced low platelets and bleeding than older unfractionated heparin, and usually needs no routine blood monitoring.

Most women manage the daily injection well within a few days. The syringe is pre-filled with your dose.

For confirmed APS, low-dose aspirin combined with LMWH is the cornerstone of treatment and one of the highest-impact interventions in obstetric medicine. Randomised trials and meta-analyses established that this combination lifts live-birth rates in APS pregnancies from roughly 25 to 30 percent to around 75 to 85 percent, and it is standard of care across FOGSI, ACOG and RCOG guidance.

The two medicines work in different ways. Aspirin reduces platelet stickiness and has anti-inflammatory effects that support the placenta. LMWH reduces clotting in the placental vessels and may also help the placenta embed properly.

Typical APS regimen (your obstetrician individualises this):

• Low-dose aspirin 75 to 150 mg daily, started ideally before conception or as soon as pregnancy is confirmed, usually continued until around 36 weeks. It costs only Rs 30 to 50 a month.
• LMWH (enoxaparin) at a preventive dose for obstetric APS, or a treatment dose if there has also been a previous clot, started in early pregnancy and continued through to six weeks after delivery.
• Hydroxychloroquine is increasingly added, especially when there are autoimmune features; it is safe in pregnancy and breastfeeding.

Delivery is planned carefully so you are not over-thinned when bleeding risk is highest, while keeping clot protection. The key is timing the last LMWH dose and the spinal or epidural safely.

• The last preventive LMWH dose is given at least 12 hours, and a treatment dose at least 24 hours, before delivery or an epidural/spinal. This avoids a rare but serious spinal bleed.
• For a planned induction or C-Section Recovery Week by Week: An India Guide (Day 1 to Month 6), the evening dose before is usually skipped to create that gap; if labour starts on its own, the team adjusts the anaesthetic plan to how recent your last dose was.
• If the gap is too short for an epidural, other pain relief is used instead.
• LMWH is usually restarted 6 to 12 hours after a vaginal birth or 12 to 24 hours after a caesarean, once bleeding is settled.

The six weeks after delivery, especially the first one to two weeks, carry the highest clot risk of the whole pregnancy, many times the non-pregnant baseline. The reasons include continued clot-prone blood, reduced movement (more so after a caesarean), tissue injury from birth, and dehydration. Clots are a recognised cause of maternal death, so this window deserves attention even in women who felt low-risk during pregnancy.

Things that raise this postpartum risk include a caesarean (especially emergency), age over 35, obesity, a previous clot, thrombophilia, preeclampsia, heavy bleeding needing transfusion, prolonged labour, a twin or multiple pregnancy, and prominent varicose veins. Guidelines such as RCOG use risk scores to decide who needs preventive LMWH and for how long, typically ten days after a caesarean with risk factors, extended to six weeks for thrombophilia or a previous clot.

For everyone, the basics help: move and walk early, stay well hydrated, and use compression stockings if advised.

Costs differ enormously between government and private care. In the government tertiary system, under JSSK and at medical colleges, the whole pathway, specialist consultations, thrombophilia testing through immunology departments, LMWH from the hospital pharmacy, monitoring, delivery and ambulance transport, is essentially free. AIIMS Delhi, PGI Chandigarh, JIPMER, KEM Mumbai and major state colleges offer comprehensive care. The trade-off is that specialist haematology services and some tests may not be available at smaller facilities, so referral and travel are sometimes needed.

In private care the bills add up: an APS panel is roughly Rs 5,000 to 10,000 per round (and you repeat it 12 weeks later), a full inherited panel adds several thousand more, and a pregnancy course of LMWH plus monitoring and growth scans can run to a few lakh. A private caesarean alone can be Rs 50,000 to 2,00,000.

Schemes soften this. Ayushman Bharat PMJAY covers up to Rs 5 lakh per family per year at empanelled hospitals for high-risk pregnancy admissions and caesareans. State schemes (Tamil Nadu CMCHIS, Karnataka Aarogya Karnataka, Andhra Pradesh Aarogyasri, Rajasthan Chiranjeevi and others) add further cover, alongside CGHS, ESI and private insurance. Keeping your records portable with an ABHA health ID is genuinely useful here, because thrombophilia care often means multiple specialists, repeat tests and referrals.

The honest bottom line: targeted testing and correctly matched treatment are worth it, especially for APS, where the gain in healthy babies is large. Cost should not block appropriate care, and the decision about what to test and when to treat should follow evidence and your individual story, not a one-size-fits-all panel. If you are planning a pregnancy with a known risk, an early discussion, alongside checks like thyroid function and Anemia in Pregnancy in India: Cutoffs, IFA, Diet & Treatment, sets you up well, as does understanding where you fall on the high-risk pregnancy framework.

• Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guideline No. 37a: Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium
• American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin: Antiphospholipid Syndrome
• ACOG Practice Bulletin: Inherited Thrombophilias in Pregnancy
• ESHRE Guideline: Recurrent Pregnancy Loss
• NHS: Antiphospholipid Syndrome (APS)
• Janani Shishu Suraksha Karyakram (JSSK), Ministry of Health and Family Welfare, Government of India